Laboratory of Reproduction and Metabolism, CEFYBO-CONICET, School of Medicine, University of Buenos Aires, Buenos Aires, Argentina; Instituto de Investigación en Biomedicina de Buenos Aires (IBioBA) - CONICET - Partner Institute of the Max Planck Society, Buenos Aires, Argentina.
Laboratory of Reproduction and Metabolism, CEFYBO-CONICET, School of Medicine, University of Buenos Aires, Buenos Aires, Argentina.
Reprod Toxicol. 2021 Sep;104:16-26. doi: 10.1016/j.reprotox.2021.06.013. Epub 2021 Jun 24.
Experimental models of maternal diabetes lead to the intrauterine programming of Gestational Diabetes Mellitus (GDM) in the offspring, together with an intrauterine proinflammatory environment, feto-placental metabolic alterations and fetal overgrowth. The aim of this work was to evaluate the effect of the mitochondrial antioxidant Idebenone given to F0 mild pregestational diabetic rats on the development of GDM in their F1 offspring and the intergenerational programming of a pro-oxidant/proinflammatory environment that affects the placentas of F2 fetuses. Control and mild pregestational diabetic female rats (F0) were mated with control males, and Idebenone or vehicle was administered to diabetic rats from day 1 of gestation to term. The F1 female offspring were mated with control males and maternal and fetal plasma samples were obtained for metabolic determinations at term. The F2 fetuses and placentas were weighed, and placental protein levels and peroxynitrite-induced damage (immunohistochemistry), mRNA levels (PCR), nitric oxide production (Griess reaction), and number of apoptotic cells (TUNEL) were evaluated. The F1 offspring of F0 diabetic rats (treated or not with Idebenone) developed GDM. The placentas of GDM rats showed a decrease in the mRNA levels of manganese superoxide dismutase and an increase in the production of nitric oxide, peroxynitrite-induced damage, and connective tissue growth factor levels, alterations that were prevented by the maternal Idebenone treatment in F0 rats. In conclusion, the maternal treatment with Idebenone in pregestational diabetic F0 rats ameliorates the pro-oxidant/proinflammatory environment that affects the placentas of F2 fetuses, although it does not prevent F1 rats from developing GDM.
实验性母体糖尿病模型导致后代发生妊娠期糖尿病(GDM),同时伴有宫内前炎症环境、胎-胎盘代谢改变和胎儿过度生长。本研究旨在评估在 F0 轻度孕前糖尿病大鼠中给予线粒体抗氧化剂 Idebenone 对其 F1 后代中 GDM 发展的影响,以及影响 F2 胎儿胎盘的促氧化/前炎症环境的代际编程。对照和轻度孕前糖尿病雌性大鼠(F0)与对照雄性大鼠交配,从妊娠第 1 天至足月给予糖尿病大鼠 Idebenone 或载体。F1 雌性后代与对照雄性大鼠交配,并在足月时获得母代和胎代血浆样本进行代谢测定。称重 F2 胎儿和胎盘,并评估胎盘蛋白水平和过氧亚硝酸盐诱导的损伤(免疫组织化学)、mRNA 水平(PCR)、一氧化氮产生(Griess 反应)和凋亡细胞数量(TUNEL)。F0 糖尿病大鼠(用或不用 Idebenone 治疗)的 F1 后代发生 GDM。GDM 大鼠的胎盘显示锰超氧化物歧化酶的 mRNA 水平降低,一氧化氮产生、过氧亚硝酸盐诱导的损伤和结缔组织生长因子水平增加,这些改变在 F0 大鼠中用 Idebenone 治疗得到预防。总之,在 F0 孕前糖尿病大鼠中用 Idebenone 进行母体治疗可改善影响 F2 胎儿胎盘的促氧化/前炎症环境,尽管不能预防 F1 大鼠发生 GDM。